A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Completed · Phase 1

Conditions studied: Geographic Atrophy

In brief

This multicenter study will investigate the safety, tolerability, pharmacokinetics, and immunogenicity of RO7303359 following single intravitreal (ITV) injection in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Participants will receive an ITV injection of RO7303359 in the single ascending dose stage and the maximum tolerated dose (MTD) or maximum tested dose (MTeD) of RO7303359 in the expansion stage.

Key facts

Study ID: NCT04615325
Run by: Hoffmann-La Roche
People needed: 37
Starts: 2020-12-08
Expected to finish: 2023-01-04
Last updated by the study team: 2023-03-01

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Northern California Retina Vitreous Associates — Mountain View, California, United States
Retinal Consultants Med Group — Sacramento, California, United States
California Retina Consultants - Santa Maria — Santa Maria, California, United States
Colorado Retina Associates, PC — Denver, Colorado, United States
Florida Eye Associates — Melbourne, Florida, United States
University Retina and Macula Associates, PC — Oak Forest, Illinois, United States
Associated Retinal Consultants PC — Royal Oak, Michigan, United States
Sierra Eye Associates — Reno, Nevada, United States
Western Carolina Retinal Associate PA — Asheville, North Carolina, United States
Tennessee Retina PC. — Nashville, Tennessee, United States
Austin Clinical Research LLC — Austin, Texas, United States
Retina Foundation of the Southwest — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.